Skip to main content

Table 2 Changes in parameters assessed on imaging, pre- and post- rituximab

From: Use of rituximab in idiopathic retroperitoneal fibrosis

Parameter:Pre-Rituximab
Treatment No. (%)
Post-Rituximab
Treatment No. (%)
P Value
Thickness of RPF Massa (mm)16.1 ± 4.610.4 ± 6.20.01
Craniocaudal RPF Lengtha (mm)108.6 ± 40.490.6 ± 45.90.02
Presence of Hydronephrosis7/10 (70)4/10 (40)0.37
 Unilateral5/103/10 
 Bilateral2/101/10 
Presence of Renal Atrophy (unilateral)5/10 (50)6/10 (60)1
Presence of Renal Stents1/10 (10)4/10 (40)0.3
 Unilateral1/103/10 
 Bilateral0/101/10 
Ureter Involvement10/10 (100)10/10 (100)1
 Unilateral3/105/10 
 Bilateral6/105/10 
Renal Vessel Involvement3/10 (30)3/10 (30)1
 Unilateral1/102/10 
 Bilateral2/101/10 
Common Iliac Vessel Involvement10/10 (100)10/10 (100)1
 Unilateral1/102/10 
 Bilateral9/108/10 
Imaging Type
 CT10/109/10 
 MRI0/101/10 
  1. a Mean ± SD